医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

AllAccem Announces Human Dental Product Presentation at the 2017 IADR/AADR/CADR General Session & Exhibition

2017年03月14日 PM10:09
このエントリーをはてなブックマークに追加


 

SAN CARLOS, Calif.

AllAccem, Inc., a pharmaceutical and medical device products developer and manufacturer, announced today that Karin M. Hold, PhD is presenting the poster titled “Biocompatibility of AllAccem Gingival Sealant, a New Prescription Dental Device” (Poster # 1349), on Thursday, March 23 at 3:45 PM PDT at the 95th General Session & Exhibition of the International Association for Dental Research (IADR) in conjunction with the 46th Annual Meeting of the American Association for Dental Research (AADR) and the 41st Annual Meeting of the Canadian Association for Dental Research (CADR) to be held at the Moscone Center in San Francisco, CA on March 22-25, 2017. Biocompatibility and safety results that AllAccem Gingival Sealant has generated to date indicate potential use as a prescription dental device.

About AllAccem Gingival Sealant

AllAccem Gingival Sealant is a professionally applied human dental product that is in development as an aid in the treatment of gingivitis by inhibiting bacterial adhesion to tooth surfaces. The Sealant contains a proprietary polymer (012-38) that presents a surface barrier preventing oral bacteria forming dental plaque from adhering to and colonizing on tooth surfaces at the gingival margin and gingival sulcus.

About AllAccem, Inc.

AllAccem is a medical device and pharmaceutical company that develops products for veterinary and human health care derived from the Company’s proprietary chemistry platform. AllAccem, Inc. currently manufactures, markets and sells the professional veterinary care products SANOS®, OticArmor® and CutoGuard®. AllAccem, Inc. is a privately held US corporation founded in 2005. AllAccem is focused on providing innovative approaches to existing medical device and pharmaceutical development challenges. For more information, visit http://www.allaccem.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170314005346/en/

CONTACT

AllAccem, Inc.
Jeffery A. Whiteford, PhD, 650-593-8701
Chief
Executive Officer

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Celltrion Healthcare presents the first real-world data for Truxima® (biosimilar rituximab) in patients with diffuse large B-cell lymphoma at the EHA 2021 Virtual Congress
  • セーフガードDNAダイアグノスティックス、COVID検査用のRhinostics乾式採取スワブをフィリピンにおける当社ラボの主要採取デバイスとして投入
  • Valemetostat Data at EHA Shows Promising Durable Tumor Response in Patients with Peripheral T-Cell Lymphoma and Adult T-Cell Leukemia/Lymphoma
  • Telix Launches “Gallium Wave” Awareness Website
  • セルフエスティーム・ブランズがデジタル栄養コーチング・ブランドのストロンガーUを買収